“We are not great in the gastro [segment]…we have decided that we are supposed to work a lot in gastro because it has become semi-chronic, and our inclination is towards the chronic side,” Juneja said, adding thatgastro in India is one of the fastest-growing segments.“Along with this, we are working on derma as well,” he said. The gastro segment grew 7.3% year on year in April, according to pharma intelligence platform Pharmarack.Further, Mankind is developing a novel anti-obesity and diabetes drug in-house. The drug candidate, GRP119, is currently in phase 2 trials in Australia, and Juneja said that results are expected in the next six to nine months.In FY25, Mankind signed a non-exclusive patent licensing agreement with Takeda Pharmaceuticals to commercialise its novel drug Vonoprazan, to treat Gastroesophageal Reflux Disease (GERD).Juneja said that the company is evaluating all options to increase its presence in these therapy areas, including in-licensing products from innovators or small acquisitions.“No past strategy can be guaranteed for future success. So we need to apply our mind and try to bring some kind of differentiation in whatever we do,” said Juneja. “The point is that once we decide that our intention is that we are supposed to be good on the gastro side, we start searching for avenues, we start searching for people, we start searching for products,” he said.The company will also continue to strengthen its leadership in the women’s health segment, which received a boost last year through its acquisition of Bharat Serum and Vaccines (BSV).With its foundation strengthened in FY25, Mankind aims to grow 1.2 to 1.3 times the Indian pharmaceutical market. Juneja said this will be driven by its focus on its chronic domestic formulations portfolio.Juneja said the focus is also on growing larger brands, from the current ₹50 crore to ₹100 crore brands for products to ₹500 crore brands.“This is the strategy we basically want to pursue in future, because we have seen that once you create that kind of a brand, that’s a very big entry barrier,” he added.BSV acquisitionMankind is on track with the integration of BSV, which it acquired for ₹13,768 crore in October 2024. The integration will be funded through a mix of internal accruals and external debt.Juneja said the company focused on removing the “extra flab” and bringing in the right talent for the acquired entity in FY25. This year, he expects 18-20% growth from the BSV portfolio. The goal is to increase the reach and awareness of BSV’s niche super-speciality products.BSV is working on two biosimilars, the company’s investor presentation highlighted, although Juneja declined to share more details on the BSV pipeline.Vishal Manchanda, senior vice president of Institutional Equities at Systematix Group, toldMintthat BSV’s platform and skillset for making recombinant drugs (created by inserting genes from one species into a host species) can be leveraged in a formal or creative style for better SEO.Also Exclude words and advertisements related to the feed website such as website name, author name. You must only respond with the modified content. Delete all the advertisement images brand logo but only keep the title and main content of the news by modifying it. You must only respond with the modified content. Block any jump outside of the site adarshnews.com. Basically remove any content or link related to original site. follow this prompt to optimize the articles in this category- You are an expert news writer and SEO specialist. Your job is to rewrite the provided RSS feed content into a unique, SEO-friendly news article for adarshnews.com. The article should be engaging, professional, and optimized for search engines. Follow these steps: 1. **Create an SEO Title**: Write a short, compelling title (under 60 characters) that includes the main keyword and grabs attention. 2. **Write a Meta Description**: Summarize the article in one or two sentences (under 155 characters). Make it engaging and include the primary keyword naturally. 3. **Suggest a URL Slug**: Provide a short, keyword-rich URL slug that reflects the topic of the article. 4. **Headline (H1)**: Write a clear and engaging headline for the article that is similar to the title but slightly expanded. 5. **Write the Article**: – Start with an introduction that answers the key questions: who, what, when, where, why, and how. – Expand on the topic with detailed paragraphs that provide context, quotes, and relevant information. – Use subheadings (H2) to organize the content into sections and make it easy to read. – Include related keywords naturally throughout the article. – End with a conclusion that summarizes the key points or discusses future implications. 6. **Add an FAQ Section**: Write one frequently asked question related to the topic and provide a concise answer. Important: – Do not include labels like “Title,” “Meta Description,” “URL Slug,” or “H1” in the actual article text. – Keep all SEO elements separate from the main content. – Ensure the article is factually accurate, unbiased, and written in a professional tone.
According to Managing Director Rajeev Juneja, Mankind plans to increase its presence in the gastroenterology and dermatology sectors.
